Plaque Psoriasis Research (Short)

The ONWARD study is testing an investigational oral drug called ESK-001 for the treatment of plaque psoriasis. ESK-001 works by blocking certain proteins in your immune system, which may help to reduce the severity of your plaque psoriasis and improve quality of life. In the study ESK-001 is given as a tablet that is taken every day by mouth.

​

To join the study, you must meet the following basic criteria:

• At least 18 years of age.

• Diagnosed with plaque psoriasis at least 6 months ago.

• Have plaques covering at least 10% of your body​.

​

The study lasts about 7 months and requires regular visits to the research site. The study drug will be given at no cost to you, and you will not be charged for any study-related visits, laboratory work, tests, or procedures needed for the study. In addition, you will be reimbursed for reasonable and necessary transportation, parking payments, etc. related to visiting the study site, and you may receive stipends for visits completed.

​

After you complete this study, you will have the opportunity to enter another study, called a long-term extension study, where you will receive ESK-001 long-term.